Dendreon looks to cut manufacturing costs; Express Scripts pays $2.75 million fine;

> Dendreon ($DNDN), which makes prostate cancer drug Provenge, is looking at how to make its manufacturing more efficient since the cost of producing the drug is a drag on earnings. Story

> Contract manufacturer Akela Pharma reported earning $800,000 in the last quarter compared with $3.5 million a year earlier. Item

> Biologics manufacturer Lonza has a new contract to manufacture products for Avalanche Biotechnologies, whose lead wet age-related macular degeneration gene therapy candidate AVA-101 started clinical trials last year. Item

> Fette Compacting has a new tableting center in Campinas, near São Paulo, Brazil. Item

> The pharmacy benefits manager Express Scripts will pay a $2.75 million fine to settle charges that it didn't have adequate provisions in place at distribution centers to prevent employee theft of controlled substances. Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.